9,233 reports of this reaction
1.3% of all TOFACITINIB reports
#19 most reported adverse reaction
MUSCULOSKELETAL STIFFNESS is the #19 most commonly reported adverse reaction for TOFACITINIB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 9,233 FDA adverse event reports linking TOFACITINIB to MUSCULOSKELETAL STIFFNESS. This represents approximately 1.3% of all 696,662 adverse event reports for this drug.
TOFACITINIB has an overall safety score of 85 out of 100. Patients taking TOFACITINIB who experience musculoskeletal stiffness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MUSCULOSKELETAL STIFFNESS is a less commonly reported adverse event for TOFACITINIB, but still significant enough to appear in the safety profile.
In addition to musculoskeletal stiffness, the following adverse reactions have been reported for TOFACITINIB:
The following drugs have also been linked to musculoskeletal stiffness in FDA adverse event reports:
MUSCULOSKELETAL STIFFNESS has been reported as an adverse event in 9,233 FDA reports for TOFACITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MUSCULOSKELETAL STIFFNESS accounts for approximately 1.3% of all adverse event reports for TOFACITINIB, making it a notable side effect.
If you experience musculoskeletal stiffness while taking TOFACITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.